A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent

• Tumor that can be measured by x-ray or scan

• Adequate organ function

Exclusion Criteria:

• Inability to swallow capsules

• Documented brain metastases

• Prior chemotherapy or biological therapy for this disease